GIOSTAR REVIEWS

Osteoarthritis routinely abbreviated as OA, is a common joint disorder mostly affecting middle age or elderly people. Classically, the condition was thought to be due to overuse or high pressured joints, but it has recently to be understood as the abnormality, associated with the entire joints, involving different parts such as cartilages, joint lining, ligaments and bones. The condition primarily symbolizes the breakdown of the cartilages; the tissue that is padded between the two bones for the ease of movement and lubrication. It as well specifies the deterioration of tendons, ligaments and various degree of inflammation of the joint-lining also called as synovium.   The OA is mainly prevalent for knee joints although it can be widespread to any joints of the body such as joints of hands, spine, hips and toes. However, life time risk of development of osteoarthritis is about 46% for knees, due to their weight bearing nature. Knowing your condition about Osteoarthritis ...

Currently, healthcare system is facing variety of challenges globally; finding an effective diabetes treatment is one of them. Diabetes is the Simplest version of the metabolic diseases with very remote risk factors; which are yet to be pinpointed. The symptoms of this mysterious disease can be controlled but cannot be cured completely. However, the promises made by science of regenerative medicines and stem cells, have given a new hope to the medical fraternity.             Stem cells are the unique precursor cells of the body, with the great potential to differentiate into variety of cells, on demand. This property of stem cells can as well be applied to the diseases like diabetes, wherein human body is in crisis of insulin producing beta cells; more commonly known as the pancreatic cells. This facet of regenerative medicine has sparked great interest in many scientists in order to achieve a hallmark therapy for diabetes with th...

San Diego, California-based Global Institute of Stem Cell Therapy and Research, a leader in stem cell research, has announced that they have received an approval for a COVID-19 clinical trial, led by their Indian American medical director Dr. Prabhat Soni. GIOSTAR will conduct the trial using stem cells to treat COVID-19 patients under the approval of the United States Food and Drug Administration “expanded access for compassionate use” program, said a PRNewswire report. The institute is exploring a promising alternative approach to the devastating disorder, which leverages the anti-inflammatory properties of mesenchymal stem cells (MSCs). According to Soni, the investigation is based upon two decades of stem cell research by GIOSTAR’s Indian American co-founder, chairman and chief scientific officer Dr. Anand Srivastava. The COVID-19 pandemic has resulted in unprecedented disruption, with more than 3 million cases and 200,000 deaths reported worldwide as of May 1, 2020, a f...